Citius Pharmaceuticals, Inc. (CTXR)
0.4034
+0.03
(+8.79%)
USD |
NASDAQ |
Oct 23, 16:00
0.40
0.00 (0.00%)
After-Hours: 20:00
Citius Pharmaceuticals Enterprise Value : 10.54M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 10.54M |
| October 22, 2026 | 9.644M |
| October 21, 2026 | 10.32M |
| October 20, 2026 | 10.93M |
| October 19, 2026 | 11.21M |
| October 16, 2026 | 12.09M |
| October 15, 2026 | 12.09M |
| October 14, 2026 | 12.23M |
| October 13, 2026 | 12.53M |
| October 12, 2026 | 12.99M |
| October 09, 2026 | 13.17M |
| October 08, 2026 | 12.88M |
| October 07, 2026 | 13.22M |
| October 06, 2026 | 12.66M |
| October 05, 2026 | 13.74M |
| October 02, 2026 | 14.06M |
| October 01, 2026 | 14.29M |
| September 30, 2026 | 14.04M |
| September 29, 2026 | 14.69M |
| September 28, 2026 | 14.54M |
| September 25, 2026 | 15.35M |
| September 24, 2026 | 15.12M |
| September 23, 2026 | 15.07M |
| September 22, 2026 | 15.89M |
| September 21, 2026 | 15.29M |
| Date | Value |
|---|---|
| September 18, 2026 | 15.94M |
| September 17, 2026 | 15.60M |
| September 16, 2026 | 14.84M |
| September 15, 2026 | 14.84M |
| September 14, 2026 | 15.20M |
| September 11, 2026 | 15.41M |
| September 10, 2026 | 15.53M |
| September 09, 2026 | 15.44M |
| September 08, 2026 | 15.95M |
| September 04, 2026 | 15.60M |
| September 03, 2026 | 15.99M |
| September 02, 2026 | 15.37M |
| September 01, 2026 | 15.09M |
| August 31, 2026 | 15.39M |
| August 28, 2026 | 15.99M |
| August 27, 2026 | 16.73M |
| August 26, 2026 | 15.31M |
| August 25, 2026 | 16.04M |
| August 24, 2026 | 15.26M |
| August 21, 2026 | 15.94M |
| August 20, 2026 | 15.93M |
| August 19, 2026 | 16.97M |
| August 18, 2026 | 15.16M |
| August 17, 2026 | 14.89M |
| August 14, 2026 | 20.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.92M |
| Revenue (Quarterly) | 1.494M |
| Total Expenses (Quarterly) | 10.36M |
| EPS Diluted (Quarterly) | -0.3387 |
| Gross Profit Margin (Quarterly) | -48.09% |
| Profit Margin (Quarterly) | -797.9% |
| Earnings Yield | -523.2% |
| Normalized Earnings Yield | -523.18 |